Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer

Jan Nyrop Jakobsen, Jens Benn Sørensen

    44 Citationer (Scopus)

    Abstract

    Biomarker expression is increasingly being used to customize treatment in non-small cell lung cancer (NSCLC). The choice of systemic treatment usually depends on biomarker expression in the initial diagnostic biopsy taken before initiation of first-line treatment. Chemotherapy induces DNA damages in the tumor cells, and thus, biomarker expression in the tumor after systemic treatment might not be identical to biomarker expression in the diagnostic biopsy. NSCLC is highly heterogeneous and biomarker expression may vary in different areas within the same tumor. This review explores the tumor heterogeneity and chemotherapy-induced changes in EGFR biomarker status in NSCLC.
    OriginalsprogEngelsk
    TidsskriftCancer Chemotherapy and Pharmacology
    Vol/bind69
    Udgave nummer2
    Sider (fra-til)289-99
    Antal sider11
    ISSN0344-5704
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer'. Sammen danner de et unikt fingeraftryk.

    Citationsformater